Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19

References

• Motlagh A, Yamrali M, Azghandi S, et al. COVID19 prevention & care; a cancer specific guideline. Arch Iran Med. 2020;23(4):255–264.
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337.
   PubMed Web of Science ®Google Scholar
• Desai A, Sachdeva S, Parekh T, et al. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6(6):557–559.
   PubMedGoogle Scholar
• Yu J, Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA oncol. 2020;6(7):1108–1110.
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791.
   PubMed Web of Science ®Google Scholar
• Cao S, Wylie KM, Wyczalkowski MA, et al. Dynamic host immune response in virus-associated cancers. Commun Biol. 2019;2(1):1–11.
   PubMedGoogle Scholar
• Wu JT, Kirn DH, Wein LM. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull Math Biol. 2004;66(4):605–625.
   PubMed Web of Science ®Google Scholar
• Derosa L, Melenotte C, Griscelli F, et al. The immuno-oncological challenge of COVID-19. Nat Cancer. 2020;1:946–964.
   PubMedGoogle Scholar
• Broussard G, Damania B. KSHV: immune modulation and immunotherapy. Front Immunol. 2020;10:3084.
   PubMed Web of Science ®Google Scholar
• Francescangeli F, De Angelis ML, Baiocchi M, et al. COVID-19–induced modifications in the tumor microenvironment: do they affect cancer reawakening and metastatic relapse? Frontiers in Oncology. 2020;10:2379.
   Web of Science ®Google Scholar
• Francescangeli F, De Angelis ML, Zeuner A. COVID-19: a potential driver of immune-mediated breast cancer recurrence? Breast Cancer Res. 2020;22(1):1–3.
   Web of Science ®Google Scholar
• De Cock JM, Shibue T, Dongre A, et al. Inflammation triggers Zeb1-dependent escape from tumor latency. Cancer Res. 2016;76(23):6778–6784.
   PubMed Web of Science ®Google Scholar
• Goddard ET, Bozic I, Riddell SR, et al. Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 2018;20(11):1240–1249.
   PubMed Web of Science ®Google Scholar
• Fluegen G, Avivar-Valderas A, Wang Y, et al. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat Cell Biol. 2017;19(2):120–132.
   PubMed Web of Science ®Google Scholar
• Fiorini E, Veghini L, Corbo V, et al. Modeling cell communication in cancer with organoids: making the complex simple. Front Cell Dev Biol. 2020;8:166.
   PubMed Web of Science ®Google Scholar
• Patel VG, Zhong X, Liaw B, et al. Does androgen deprivation therapy protect against severe complications from COVID-19? Ann Oncol. 2020;31(10):1419–1420.
   PubMed Web of Science ®Google Scholar
• Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n = 4532). Ann Oncol. 2020;31(8):1040–1045.
   PubMed Web of Science ®Google Scholar
• Mikkonen L, Pihlajamaa P, Sahu B, et al. Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol. 2010;317(1–2):14–24.
   PubMed Web of Science ®Google Scholar
• Goodwin PM. Androgen deprivation therapy could protect men against COVID-19. Oncol Times. 2020;42:18–19.
   Google Scholar
• Caffo O, Zagonel V, Baldessari C, et al. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. Ann Oncol. 2020;31(10):1415–1416.
   PubMed Web of Science ®Google Scholar
• Bahmad HF, Abou-Kheir W. Crosstalk between COVID-19 and prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):561–563.
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Mucci LA, Antonarakis ES, et al. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020;10(6):779–782.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Clark JI, Quinn DI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol. 2017;28(7):1484–1494.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant B, Liu W-C, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1145.
   PubMed Web of Science ®Google Scholar
• Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Mangalam AK, et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016;44(6):1379–1391.
   PubMed Web of Science ®Google Scholar
• Bazhanova E. Participation of interferon-alpha in regulation of apoptosis. J Evol Biochem Physiol. 2005;41(2):127–133.
   Web of Science ®Google Scholar
• Asmana Ningrum R. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo). 2014;2014:1–8.
   Google Scholar
• Bekisz J, Baron S, Balinsky C, et al. Antiproliferative properties of type I and type II interferon. Pharmaceuticals. 2010;3(4):994–1015.
   Google Scholar
• Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307.
   PubMed Web of Science ®Google Scholar
• Behren A, Thompson EW, Anderson RL, et al. Cancer plasticity and the microenvironment: implications for immunity and therapy response. Front Oncol. 2019;9:276.
   PubMed Web of Science ®Google Scholar
• Isgro MA, Vitale MG, Celentano E, et al. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis. J Transl Med. 2021;19(1):1–6.
   PubMed Web of Science ®Google Scholar
• Costa B, Vale N. A review of repurposed cancer drugs in clinical trials for potential treatment of COVID-19. Pharmaceutics. 2021;13(6):815.
   PubMed Web of Science ®Google Scholar
• De Guillebon E, Dardenne A, Saldmann A, et al. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. Int J Cancer. 2020;147(6):1509–1518.
   PubMed Web of Science ®Google Scholar
• Ganji A, Farahani I, Khansarinejad B, et al. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis. 2020;83:102437.
   PubMed Web of Science ®Google Scholar
• Rearigh L, Stohs E, Freifeld A, et al. De-escalation of empiric broad spectrum antibiotics in hematopoietic stem cell transplant recipients with febrile neutropenia. Ann Hematol. 2020;99(8):1917–1924.
   PubMed Web of Science ®Google Scholar
• Kattan J, Kattan C, Assi T. Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection? Future Med. 2020;12:351–354.
   Google Scholar
• Sun X, Roudi R, Dai T, et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer. 2019;19(1):1–13.
   PubMedGoogle Scholar
• Buonaguro FM, Puzanov I, Ascierto PA. Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 2020;18(1):165.
   PubMed Web of Science ®Google Scholar
• Arnaldez FI, O’Day SJ, Drake CG, et al. The society for immunotherapy of cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020;8(1):e000930.
   PubMed Web of Science ®Google Scholar
• Di-Cosimo S, Malfettone A, Perez-Garcia JM, et al. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. Eur J Cancer. 2020;135:62–65.
   PubMed Web of Science ®Google Scholar
• Maio M, Hamid O, Larkin J, et al. Immune checkpoint inhibitors for cancer therapy in the COVID-19 era. Clin Cancer Res. 2020;26(16):4201–4205.
   PubMed Web of Science ®Google Scholar
• Vivarelli S, Falzone L, Torino F, et al. Immune-checkpoint inhibitors from cancer to COVID‑19: a promising avenue for the treatment of patients with COVID‑19. Int J Oncol. 2021;58(2):145–157.
   PubMed Web of Science ®Google Scholar
• Sobhani N, Tardiel-Cyril DR, Davtyan A, et al. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel). 2021;13(6):1440.
   PubMed Web of Science ®Google Scholar
• We SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844.
   PubMed Web of Science ®Google Scholar
• Hartog NL, Davis AT, Prokop JW, et al. Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab. Ann Allergy Asthma Immunol. 2021;126(3):306–308.
   PubMedGoogle Scholar
• Flament H, Rouland M, Beaudoin L, et al. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021;22(3):322–335.
   PubMed Web of Science ®Google Scholar
• Liu B, Li M, Zhou Z, et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.
   PubMed Web of Science ®Google Scholar
• Sharma G, Ojha R, Noguera-Ortega E, et al. PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma. JCI Insight. 2020;5(17):e133225.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020;10(5):766–788.
   PubMed Web of Science ®Google Scholar
• Mohindra P, Buckey CR, Chen S, et al. Radiation therapy considerations during the COVID‐19 Pandemic: literature review and expert opinions. J Appl Clin Med Phys. 2020;21(5):6–12.
   PubMedGoogle Scholar
• Whitaker M, Kron T, Sobolewski M, et al. COVID-19 pandemic planning: considerations for radiation oncology medical physics. Phys Eng Sci Med. 2020;43(2):473–480.
   PubMedGoogle Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Takano N, Yamada Y, Tokuhisa M, et al. Identification of the molecular target of azithromycin as an autophagy inhibitor and its potential application in cancer therapeutics. AACR. 2020;80:1227.
   Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
   PubMed Web of Science ®Google Scholar
• Gendrot M, Andreani J, Jardot P, et al. In vitro antiviral activity of doxycycline against SARS-CoV-2. Molecules. 2020;25(21):5064.
   PubMed Web of Science ®Google Scholar
• Obispo B, Rogado J, Serrano-Montero G, et al. 1771P Do breast cancer patients with COVID-19 have a poor prognosis? Experience in a hospital in Madrid. Ann Oncol. 2020;31:S1028.
   Google Scholar
• Petroni G, Bagni G, Iorio J, et al. Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K. Cell Death Dis. 2020;11:1–18.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Hino H, Moriya S, et al. Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin. Biochem Biophys Rep. 2020;22:100750.
   PubMedGoogle Scholar
• Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020;35:100684.
   PubMed Web of Science ®Google Scholar
• Shrimp JH, Kales SC, Sanderson PE, et al. An enzymatic TMPRSS2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of COVID-19. ACS Pharmacol Transl Sci. 2020;3(5):997–1007.
   PubMedGoogle Scholar
• Breining P, Frolund AL, Hojen JF, et al. Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2021;128(2):204–212.
   PubMed Web of Science ®Google Scholar
• Lau B, Crumbaker M, Yam AOW, et al. A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): dose escalation results. J Clin Oncol. 2021;39(6_suppl):114.
   Web of Science ®Google Scholar
• Udupa A, Leverenz D, Balevic SJ, et al. Hydroxychloroquine and COVID-19: a rheumatologist’s take on the lessons learned. Curr Allergy Asthma Rep. 2021;21(1):1–10.
   Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:1–4.
   PubMed Web of Science ®Google Scholar
• Basile MS, Mazzon E, Krajnovic T, et al. Anticancer and differentiation properties of the nitric oxide derivative of lopinavir in human glioblastoma cells. Nolecules. 2018;23:2463.
   Web of Science ®Google Scholar
• Anastasiou IA, Eleftheriadou I, Tentolouris A, et al. In vitro data of current therapies for SARS-CoV-2. Curr Med Chem. 2020;27(27):4542–4548.
   PubMed Web of Science ®Google Scholar
• Ripani P, Delp J, Bode K, et al. Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain. Oncogene. 2020;39(11):2345–2357.
   PubMed Web of Science ®Google Scholar
• Logan SA, Brissenden AJ, Szewczuk MR, et al. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly (d, l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival. Drug Des, Dev Ther. 2017;11:2239.
   PubMed Web of Science ®Google Scholar
• Zhang W-F, Stephen P, Theriault J-F, et al. Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. J Phys Chem Lett. 2020;11(11):4430–4435.
   PubMed Web of Science ®Google Scholar
• Dunn LA, Fury MG, Sherman EJ, et al. Phase I study of induction chemotherapy with Afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus‐associated oropharyngeal squamous cell cancer. Head Neck. 2018;40(2):233–241.
   PubMed Web of Science ®Google Scholar
• Tan J, Ye J, Song M, et al. Ribavirin augments doxorubicin’s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin‐induced eIF4E activation. J Biochem Mol Toxicol. 2018;32(1):e22007.
   Web of Science ®Google Scholar
• Isono M, Sato A, Asano T, et al. Delanzomib interacts with ritonavir synergistically to cause endoplasmic reticulum stress in renal cancer cells. Anticancer Res. 2018;38(6):3493–3500.
   PubMed Web of Science ®Google Scholar
• El-Bairi K, Trapani D, Petrillo A, et al. Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer. 2020;141:40–61.
   PubMed Web of Science ®Google Scholar
• Xu K, Cai H, Shen Y, et al. Management of Corona virus disease-19 (COVID-19): the Zhejiang experience. J Zhejiang Univ. 2020;49:147–157.
   Google Scholar
• Gao J, Zhang L, Liu X, et al. Repurposing low-molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2. J Phys Chem Lett. 2020;11(17):7267–7272.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:1–18.
   PubMed Web of Science ®Google Scholar
• Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–468.
   PubMed Web of Science ®Google Scholar
• White KM, Rosales R, Yildiz S, et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021;371(6532):926–931.
   PubMed Web of Science ®Google Scholar
• Kindrachuk J, Ork B, Hart BJ, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015;59(2):1088–1099.
   PubMed Web of Science ®Google Scholar
• Patterson BK, Seethamraju H, and Dhody K, et al. Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. Medrxiv. 2020 https://doi.org/https://doi.org/10.1101/2020.05.02.20084673.
   Google Scholar
• Uddin MH, Zonder JA, Azmi AS. Exportin 1 inhibition as antiviral therapy. Drug Discov Today. 2020;25(10):1775–1781.
   PubMed Web of Science ®Google Scholar
• Pollard BS, Blanco JC, Pollard J. Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy. vivo. 2020;34(6):3723–3730.
   PubMed Web of Science ®Google Scholar
• Reddy D, Kumavath R, Barh D, et al. Anticancer and antiviral properties of cardiac glycosides: a review to explore the mechanism of actions. Molecules. 2020;25(16):3596.
   Web of Science ®Google Scholar
• Souza KFC, Souza BPTM, de Palmer Paixao ICN, et al. Na+/K+-ATPase as a target of cardiac glycosides for the treatment of SARS-CoV-2 Infection. Front Pharmacol. 2021;12:624704.
   PubMed Web of Science ®Google Scholar
• Newman RA, Sastry KJ, Arav-Boger R, et al. Antiviral effects of oleandrin. J Exp Pharmacol. 2020;12:503–515.
   PubMedGoogle Scholar
• Corti C, Curigliano GJ. Commentary: SARS-CoV-2 vaccines and cancer patients. Ann Oncol. 2021;32(4):569–571.
   PubMed Web of Science ®Google Scholar
• Yazaki S, Yoshida T, Kojima Y, et al. Difference in SARS-CoV-2 antibody status between patients with cancer and health care workers during the COVID-19 pandemic in Japan. JAMA Oncol. 2021;7(8):1141–1148.
   PubMed Web of Science ®Google Scholar
• Eliakim-Raz N, Massarweh A, Stemmer A, et al. Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment. JAMA Oncol. 2021. DOI:https://doi.org/10.1001/jamaoncol.2021.4390.
   Google Scholar
• Agha M, Blake M, Chilleo C et al. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. Open Forum Infect Dis. 2021;8(7):ofab353.
   PubMed Web of Science ®Google Scholar
• Haq EU, Yu J, Guo J, et al. Frontiers in the COVID-19 vaccines development. Exp Hematol Oncol. 2020;9(1):1–6.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020;21(1):39–51.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020;21(2):181–192.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397:99–111.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11:1–7.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488.
   PubMed Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–588.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897.
   PubMed Web of Science ®Google Scholar
• Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel). 2019;7(2):37.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wohlford-Lenane C, Zhao J, et al. Intranasal treatment with poly (I· C) protects aged mice from lethal respiratory virus infections. J Virol. 2012;86(21):11416–11424.
   PubMed Web of Science ®Google Scholar
• Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218–1223.
   PubMed Web of Science ®Google Scholar